SCHEMBL30753293

SCHEMBL30753293

COc1ccnc(C(=O)C2CC(F)(F)C2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 3/20 0.42
KDM2B Q8NHM5 1/20 0.41
CCR1 P32246 1/20 0.41
CCR5 P51681 1/20 0.41
CCR8 P51685 1/20 0.41
GRM5 P41594 1/20 0.39
NOS3 P29474 2/20 0.39
NOS1 P29475 2/20 0.39
NOS2 P35228 2/20 0.39
ABL1 P00519 1/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
GRM4 Q14833 1/20 0.37
PLAU P00749 1/20 0.37
LMNA P02545 1/20 0.37
RIOK2 Q9BVS4 1/20 0.36
KDM1A O60341 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30753282 0.83 RAB9A (0.49) CCR1CCR5CCR8GRM5NOS3
SCHEMBL31175929 0.75 CCR1 (0.52) CCR1CCR5CCR8GRM5NOS3
SCHEMBL1703544 0.75 CCR1 (0.52) CCR1CCR5CCR8GRM5NOS3
SCHEMBL29455922 0.73 ALDH1A1 (0.55) CCR1CCR5CCR8GRM5NOS3
SCHEMBL2915719 0.73 CCR1 (0.53) CCR1CCR5CCR8GRM5NOS3
SCHEMBL1023538 0.73 ALDH1A1 (0.55) CCR1CCR5CCR8GRM5NOS3
SCHEMBL27071638 0.72 CCR1 (0.44) CCR1CCR5CCR8GRM5NOS3
SCHEMBL28957013 0.72 ALDH1A1 (0.53) CCR1CCR5CCR8GRM5NOS3
Hydrochloric Acid SCHEMBL6640953 0.72 ALDH1A1 (0.53) CCR1CCR5CCR8GRM5NOS3
SCHEMBL2624147 0.72 KDM4E (0.54) CCR1CCR5CCR8GRM5NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4565587-A1 DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF 4B Technologies (Beijing) Co., Limited (CN) 2025-06-11 EP disclosed
US-20250154153-A1 DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) 2025-05-15 US disclosed
WO-2024027116-A1 DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154153-A1 DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF PLA2G4A, PLA2G1B, PLA2G4B OPRM1 4236/4885KDM2B 2128/4885CCR1 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.